Sclerotherapy for congenital lesions in the head and neck.
OBJECTIVE
This study retrospectively reviews the results of sclerotherapy using several sclerosants for congenital lesions of the head and neck.


METHODS
Between May 1990 and May 2002, patients with lymphatic malformations were treated by sclerotherapy; 10 with bleomycin, and 25 with OK-432. OK-432 sclerotherapy was also applied in 9 patients with plunging ranula and in 1 patient with branchial anomaly. Percutaneous sclerotherapy with ethanolamine oleate was used in 29 patients with venous malformations, and 28 patients with pyriform sinus fistula were treated by trichloroacetic acid chemocauterization.


RESULTS
Overall, two thirds of patients with these lesions showed marked to complete response. One case of mortality occurred in the bleomycin sclerotherapy group. However, no major complications by other sclerosants were found. In lymphatic malformations, history of excision before sclerotherapy was a poor prognostic factor.


CONCLUSIONS
Sclerotherapy using these sclerosants is a safe and effective primary treatment for congenital lesions in the head and neck.
Kim
Kwang Hyun
KH
Department of Otolaryngology-Head and Neck Surgery, Cancer Research Institute, Seoul, Korea. kimkwang@plaza.snu.ac.kr
Sung
Myung-Whun
MW
Roh
Jong-Lyel
JL
Han
Moon Hee
MH
D000293:Adolescent; D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006257:Head; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008206:Lymphatic Diseases / Q000151:congenital* / Q000628:therapy*; D008208:Lymphatic System / Q000002:abnormalities*; D008297:Male; D009333:Neck; D010844:Picibanil / Q000627:therapeutic use; D012189:Retrospective Studies; D015911:Sclerotherapy
D001761:Bleomycin; D010844:Picibanil